Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA017094-11
Application #
3961838
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Jagadish, Bhumasamudram; Ozumerzifon, Tarik J; Roberts, Sue A et al. (2014) IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS. Synth Commun 44:
Barr, Paul M; Miller, Thomas P; Friedberg, Jonathan W et al. (2014) Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 124:1259-65
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87

Showing the most recent 10 out of 314 publications